Aevice Health and NUHS Launches Study To Detect Lung Sounds Abnormalities using Wearable Respiratory Monitor In Paediatric Patients

Press Release

Announcements

Aevice Health and NUHS Launches Study To Detect Lung Sound Abnormalities Using Wearable Respiratory Monitor In Paediatric Patients

 

  • Held at National University Hospital (NUH), the study will validate the use of a wearable respiratory monitor, the AeviceMD, to detect lung sound abnormalities, such as wheezing.

 

  • The study builds on Aevice Health’s research collaboration with A*STAR Singapore to develop a predictive model for asthma attack among children.

 

Singapore, 27 October 2021 Aevice Health, Singapore-based MedTech company dedicated to improving the lives of 545 million people with chronic respiratory disease, and the National University Health System (NUHS) today announced the launch of a study to use a novel respiratory monitor to detect lung sound abnormalities. The study, coordinated and facilitated by the NUHS Centre for Innovation in Healthcare (CIH), will investigate the use of Aevice Health’s proprietary wearable – the AeviceMD – in detecting wheezing in paediatric patients with breathing difficulties at the National University Hospital (NUH). Recruitment of study participants begun in September 2021 and the study is expected to conclude by the second quarter of 2022.

Wheezing is one of the key signs of respiratory diseases such as asthma, and asthma is one of the most prevalent chronic diseases of childhood. It is estimated to affect 14% of children worldwide. In Singapore, the disease affects about one in five children[1]. Many studies have shown that the chronic disease can be difficult to manage in children due to their inability to verbalise their symptoms or even realise that they are experiencing an exacerbation. This could lead to under-diagnosis, under-treatment and inadequate control of the disease[2].

The AeviceMD is a wearable respiratory monitor that detects and records chest sounds remotely and continuously. The chest sounds are then analysed and translated into heart rate and respiratory rate measurements, while abnormalities such as wheezing are flagged. Barely bigger than a US half-dollar coin and weighing less than 10 grams, the AeviceMD combines extremely comfortable and child-friendly form factor with highly accurate, longitudinal patient data to provide a new standard for remote patient monitoring.

“Aevice Health has developed a device that could allow the remote assessment of lung sounds in patients presenting with respiratory illnesses. The ability of the device to quantify wheeze and capture other lung sounds remotely will be studied in an upcoming clinical trial. It can potentially enhance remote patient monitoring and may be useful in situations such as the current COVID-19 pandemic where there is a need to minimise contact with patients. This ability to detect abnormal lung sounds may also find usefulness in homes to identify wheezing early in children and allow for prompt attention by the caregiver.” said Dr Michael Lim, Principal Investigator of the study and Senior Consultant, Division of Padiatric Pulmonary Medicine and Sleep, Department of Paediatrics, Khoo Teck Puat – National University Children’s Medical Institute, NUH.

“Currently, there is no widely adopted solution in market that is able to objectively identify and analyze lung sound abnormalities continuously and remotely in patients. This study will further validate AeviceMD’s value to providers and patients by empowering the detection of lung sound abnormalities objectively, continuously, and remotely to further bridge the gap between providers and clinicians,” said Adrian Ang, Chief Executive Officer of Aevice Health.

Concurrently, the company is working towards conducting research and development on a predictive model for asthma attack among children using continuous measures from a wearable device. The study, a collaboration with partners in Singapore, will potentially unlock insights into how clinicians and researchers can use continuous measurement of physiological signals to detect early signs of asthma attacks.

“This study, alongside our research collaboration on the predictive model, will have a significant and profound impact on the way we understand chronic respiratory disease. The use of AeviceMD as a novel remote respiratory monitor can unlock insights beyond the hospital for providers to better understand factors leading up to an exacerbation to allow for more tailored and patient-centered outcomes. We are excited by how the use of the AeviceMD can enhance the way chronic respiratory disease is being treated and understood,” Ang added.

Earlier in July, Aevice Health announced its Pre-Series A funding from investors Toho Holdings Co Ltd, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures, and SEEDS Capital, the investment arm of government agency Enterprise Singapore. Part of the funding will be used to power the study as part of the company’s and its investors’ commitment to improve the management and understanding of chronic respiratory disease.

 

[1] Asthma (Common Childhood Illnesses), Health Hub Singapore

[2] Challenges in the treatment of asthma in children and adolescents

 

About Aevice Health

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.

The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform.

In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives.

More information about the company can be found at www.aevice.com.

About NUHS CIH

The NUHS Centre for Innovation in Healthcare (CIH) is one of six NUHS Centres of Excellence (CoEs) location at Alexandra Hospital.  It aims to develop and implement new models of care, incorporating smart technologies as well as innovations in research and training to meet present and future national healthcare needs. CIH actively facilitates inter-disciplinary research, innovation and enterprise across science, engineering and other disciplines and provides a one-stop ecosystem to testbed solutions including new devices, technologies and work processes, at scale.

About National University Hospital

The National University Hospital is a tertiary hospital and major referral centre with over 50 medical, surgical and dental specialties, offering a comprehensive suite of specialist care for adults, women and children. It is the only public hospital in Singapore to offer a paediatric kidney and liver transplant programme, in addition to kidney, liver and pancreas transplantation for adults.

The hospital was opened on 24 June 1985 as Singapore’s first restructured hospital. Each year, the Hospital attends to more than one million patients.

As an academic health institution, patient safety and good clinical outcomes are the focus of the Hospital. It plays a key role in the training of doctors, nurses, allied health and other healthcare professionals. Translational research is pivotal in the Hospital’s three-pronged focus, and paves the way for new cures and treatment.

A member of the National University Health System, it is the principal teaching hospital of the NUS Yong Loo Lin School of Medicine and the NUS Faculty of Dentistry.

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

Yvonne Lee
National University Health System
Email: Yvonne_Lee@nuhs.edu.sg

Justine LAI
Assistant Manager, Group Communications Office
National University Health System
Mobile: 97380669
Email: justine_lai@nuhs.edu.sg

 

View other articles:
This is Aevice
Our Solutions
Legal

Privacy & Terms

Resources
Contact Us
This is Aevice
Our Solutions
Legal

Privacy & Terms

Contact Us
Resources
ISO13485 Certified

Copyright © 2021 Aevice Health. All rights reserved.
ISO13485 Certified

Aevice Health is selected for Sunway iLabs Pre-Accelerator Programme

Announcements

Announcements

Aevice Health is selected for Sunway iLabs Pre-Accelerator Programme

Malaysia, 5 July, 2021 – Aevice Health is pleased to announce that we are part of the Top 23 startups selected for Sunway iLabs Pre-Accelerator Programme.

The Sunway iLabs Accelerator Programme is designed to bring selected startups to the next level. Selected startups will have access to markets, mentors, and money. Selected startups will go through a 1-month pre-accelerator, of which only the Top 5 will qualify for the investment and pilot projects with Sunway through the next 3-months accelerator.

The Pre-Accelerator Programme will start on 5 July 2021.

Read more about the programme here.

 

View other articles:
This is Aevice
Our Solutions
Legal

Privacy & Terms

Resources
Contact Us
This is Aevice
Our Solutions
Legal

Privacy & Terms

Contact Us
Resources
ISO13485 Certified

Copyright © 2021 Aevice Health. All rights reserved.
ISO13485 Certified

Aevice Health Raises S$2.8M to Expand Remote Respiratory Monitoring into Japan

Press Release

Press Release

Aevice Health Raises S$2.8M to Expand Remote Respiratory Monitoring into Japan

Singapore, 15 June 2021  Aevice Health, a Singapore-based MedTech company developing novel wearables for remote respiratory monitoring, today announced it has entered a strategic collaboration with Toho Holdings (TSE:8129) and raised a S$2.8M Pre-Series A funding round with participation from Toho Holdings Co Ltd, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures, and SEEDS Capital, the investment arm of government agency Enterprise Singapore. The new capital will position Aevice Health to further develop its proprietary technology and expand its remote respiratory monitoring solution into Japan to augment the country’s telehealth landscape.

Aevice Health will work with its strategic investor, Toho Holdings Co., Ltd., wholesaler of medicine, medical tools, and equipment with over 700 pharmacies across Japan, to develop and commercialize its remote patient monitoring solution, AeviceMD. The collaboration will provide patients with chronic respiratory diseases in the nation with a tool to stay connected to their healthcare provider, anytime anywhere.

“The pandemic has accelerated the growth and adoption of telehealth, transforming the way patients interact with their healthcare providers. The AeviceMD is a cutting-edge solution that provides patients with a continuum of comprehensive and personalized care remotely. We are thrilled to be partnering Toho Holdings and to have the backing of our investors to position Aevice Health at the forefront of the telehealth industry in Japan,” said Adrian Ang, Chief Executive Officer of Aevice Health.

Chronic respiratory diseases remain the top few leading causes of death in Japan. In 2019, lower respiratory tract infection, lung cancer, and COPD (chronic obstructive pulmonary disease) rank fourth, fifth, and ninth in top causes of total number of deaths in the year[1]. Many of these patients, particularly the elderly with higher comorbidities, require regular check-ups and constantly monitoring. With the disparity in the number of physicians between urban and rural parts of Japan widening[2], many patients living in rural parts of Japan may face difficulties accessing regular care for their chronic conditions.

The company’s flagship device, AeviceMD, is a wearable smart stethoscope that complements telehealth services to facilitate self-management of chronic diseases. Powered by artificial intelligence, it listens to the patient’s chest sounds remotely, continuously and in real time, and detects cardiopulmonary abnormalities (such as wheezing) that are typical of chronic respiratory diseases so that patients can receive fast and targeted care on time from the comfort of their homes. With its robust system packed into a miniaturized sensor, the device sits comfortably on the patient’s chest for hours of continuous monitoring. Overtime, the AeviceMD can help healthcare providers to understand how treatments uniquely impact patient symptoms, enabling them to personalize treatment to optimize patient outcomes.

“We are excited to partner with Aevice Health to support their breakthrough technology to bring positive impact to the future of telemedicine,” said David Liebreich, Chairman of KK eHealthcare, Toho Holding’s Digital Health Subsidiary.

“Pureland Group Venture has long recognized the opportunities and impact present in the digitalization of healthcare. Aevice Health’s innovative solution, which happens to be at the nexus of healthcare and digital technology, has the potential to become a leader in this new frontier. We look forward to being part of their journey as they bring their transformational remote patient monitor into regional markets,” said Mark Wang, Partner, Pureland Group Venture.

“Aevice Health is a homegrown company providing a novel and relevant solution in today’s post-pandemic climate. It has the potential to help health systems deliver quality care to their patients from the comfort of their homes, and we are excited to support them in their journey in improving patient outcomes”, said Tan Kaixin, General Manager, SEEDS Capital.

This investment comes just months after Aevice Health’s partnership with THB Global, leading tech-enabled home care, healthcare, and chronic disease management company with offices in Singapore, Dubai (UAE), and Karachi (Pakistan), to advance remote monitoring of chronic respiratory diseases in the MENASA region (Middle East, North Africa, and South Asia).

 “This new funding is a validation of our solution and a reflection of the confidence in the management team to continue delivering value to our stakeholders. With the support of our investors and partners, we will continue to accelerate our global footprint, advance our remote patient monitoring pipeline, and develop new ways of enhancing workflows of hospitals, pharmaceutical companies, insurers, and health systems to re-envision the future of respiratory care,” Ang added.

 

[1] Institute for Health Metrics and Evaluation, Japan

[2] Aging of hospital physicians in rural Japan: A longitudinal study based on national census data

About Aevice Health

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges.

The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform.

In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives.

More information about the company can be found at www.aevice.com.

 

For media enquiries, please contact:

Janelle Low
Aevice Health Pte Ltd
Email: janellelow@aevice.com

 

View other articles:
This is Aevice
Our Solutions
Legal

Privacy & Terms

Resources
Contact Us
This is Aevice
Our Solutions
Legal

Privacy & Terms

Contact Us
Resources
ISO13485 Certified

Copyright © 2021 Aevice Health. All rights reserved.
ISO13485 Certified